摘要
目的:研究参连复脉颗粒对心房颤动(房颤)大鼠心电图变化以及炎症反应与氧化应激相关指标的影响。方法:采用SD大鼠进行乙酰胆碱-氯化钙(Ach-CaCl_(2))尾静脉注射建立房颤模型,将模型大鼠随机分为模型组、维拉帕米组、参连复脉颗粒组(低、中、高剂量3组),以SD大鼠为正常对照。各组分别连续处理4周后,使用多导生理记录仪描记心电图;采用酶联免疫吸附法(ELISA)检测血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及诱导型一氧化氮合酶(iNOS)水平。结果:与正常组比较,模型组大鼠的房颤持续时间延长(P<0.05),血清TNF-α、IL-6、iNOS水平显著升高(P<0.05);与模型组比较,参连复脉颗粒中剂量组与高剂量组心电图PR间期、房颤持续时间均明显缩短(P<0.05),血清TNF-α、IL-6和iNOS水平显著降低(P<0.05)。结论:中药参连复脉颗粒可改善Ach-CaCl_(2)诱发的大鼠房颤模型炎症反应及氧化应激水平,在抑制房颤过程中发挥潜在作用。
Objective:To study the effects of Shenlian Fumai Granules on electrocardiogram changes,inflammatory response,and oxidative stress related indicators in rats with atrial fibrillation(AF).Methods:SD rats were injected with acetylcholine-calcium chloride(Ach-CaCl_(2))through tail vein to establish AF model.The model rats were randomly divided into model group,Verapamil group,and Shenlian Fumai Granules group(low-,medium-,and high-dose groups).SD rats were used as normal control.After 4 consecutive weeks of treatment in each group,electrocardiograms were recorded using a multi-channel physiological recorder.Detection of serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and inducible nitric oxide synthase(iNOS)using enzyme-linked immunosorbent assay(ELISA).Results:Compared with the normal group,the duration of AF in the model group rats was prolonged(P<0.05),and the levels of serum TNF-α,IL-6 and iNOS levels were significantly increased(P<0.05).Compared with the model group,the medium-dose and high-dose groups of Shenlian Fumai Granules significantly shortened the electrocardiogram PR interval and duration of AF(P<0.05),and the levels of serum TNF-α,IL-6 and iNOS were significantly reduced(P<0.05).Conclusion:The Chinese medicine Shenlian Fumai Granules can improve the inflammatory response and oxidative stress levels in Ach-CaCl_(2)induced AF models in rats,and play a potential role in inhibiting the process of AF.
作者
马征
曲信彦
胡敏勇
李波
MA Zheng;QU Xinyan;HU Minyong;LI Bo(The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincial Hospital of Chinese Medicine),Hangzhou Zhejiang 310006,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《新中医》
CAS
2023年第13期1-6,共6页
New Chinese Medicine
基金
国家自然科学基金项目(81874458)
北京中医药大学基本科研业务费项目(2019-JYB-XS-218)